MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX …
MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX …
Filed under: drug treatment news
The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company …
Read more on Sacramento Bee
Va. eliminates waiting list for AIDS drug assistance program for low-income …
Filed under: drug treatment news
In November 2010, the state restricted eligibility to children, pregnant women, and people receiving treatment for potentially fatal infections that exploit weakened immune systems. The restrictions were imposed because of budget constraints. They were …
Read more on Washington Post
Drug-eluting balloon procedure can effectively treat peripheral artery disease
Filed under: drug treatment news
Use of balloon angioplasty and placement of stents to widen clogged arteries have become standard medical procedure. Further advancing this treatment, drug-eluting devices are now delivering medication directly to the site where it can be most effective.
Read more on News-Medical.net
MAP Pharm Resubmits NDA To FDA For Levadex Orally Inhaled Migraine Drug
MAP Pharm Resubmits NDA To FDA For Levadex Orally Inhaled Migraine Drug … Read News
MAP Pharmaceuticals Resubmits New Drug Application To FDA For LEVADEX® Orally Inhaled Migraine DrugMOUNTAIN VIEW, Calif., Oct. 16, 2012 /PRNewswire/ — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has resubmitted its New Drug Application (NDA) to the United States Food and Drug Administration … Read News